Schedule of Investments
ARK Genomic Revolution ETF
April 30, 2020 (Unaudited)
Investments | Shares | Value | ||||||
COMMON STOCKS–99.9% | ||||||||
Biotechnology - 65.1% | ||||||||
AquaBounty Technologies, Inc.* | 536,675 | $ | 955,281 | |||||
Arcturus Therapeutics Holdings, Inc.*† | 2,028,655 | 69,988,598 | ||||||
Bellicum Pharmaceuticals, Inc.* | 56 | 280 | ||||||
CareDx, Inc.* | 922,663 | 23,417,187 | ||||||
Castle Biosciences, Inc.* | 258,084 | 7,982,538 | ||||||
Cellectis SA (France)*(a) | 1,570,329 | 20,492,793 | ||||||
Cellular Biomedicine Group, Inc.* | 467,840 | 6,783,680 | ||||||
CRISPR Therapeutics AG (Switzerland)* | 1,256,589 | 62,131,270 | ||||||
Editas Medicine, Inc.* | 1,227,418 | 28,377,904 | ||||||
Evogene Ltd. (Israel)* | 299,878 | 329,866 | ||||||
Fate Therapeutics, Inc.* | 649,834 | 17,792,455 | ||||||
Incyte Corp.* | 239,141 | 23,354,510 | ||||||
Inovio Pharmaceuticals, Inc.* | 1,059,785 | 12,749,214 | ||||||
Intellia Therapeutics, Inc.*† | 2,571,206 | 34,634,145 | ||||||
Invitae Corp.* | 4,222,336 | 69,879,661 | ||||||
Ionis Pharmaceuticals, Inc.* | 132,067 | 7,333,681 | ||||||
Iovance Biotherapeutics, Inc.* | 1,086,513 | 34,931,393 | ||||||
Organovo Holdings, Inc.*† | 7,649,779 | 3,236,621 | ||||||
Pluristem Therapeutics, Inc.* | 772,829 | 7,086,842 | ||||||
Precigen, Inc.* | 351 | 1,264 | ||||||
Seres Therapeutics, Inc.* | 2,491,493 | 9,168,694 | ||||||
Syros Pharmaceuticals, Inc.* | 2,163,509 | 18,238,381 | ||||||
Twist Bioscience Corp.* | 754,024 | 24,664,125 | ||||||
Veracyte, Inc.* | 909,919 | 24,540,515 | ||||||
Total Biotechnology | 508,070,898 | |||||||
Health Care Equipment & Supplies - 3.1% | ||||||||
Cerus Corp.* | 3,945,840 | 24,266,916 | ||||||
Health Care Providers & Services - 2.9% | ||||||||
Guardant Health, Inc.* | 289,931 | 22,313,090 | ||||||
Health Care Technology - 0.9% | ||||||||
Teladoc Health, Inc.* | 43,067 | 7,088,398 | ||||||
Life Sciences Tools & Services - 26.3% | ||||||||
10X Genomics, Inc., Class A* | 75,059 | 5,994,962 | ||||||
Adaptive Biotechnologies Corp.* | 123,226 | 3,944,464 | ||||||
Codexis, Inc.* | 1,158,096 | 13,445,494 | ||||||
Compugen Ltd. (Israel)*† | 4,243,237 | 61,484,504 | ||||||
Illumina, Inc.* | 219,594 | 70,057,074 | ||||||
NanoString Technologies, Inc.* | 598,280 | 19,001,373 | ||||||
Pacific Biosciences of California, Inc.* | 5,412,015 | 17,886,710 | ||||||
Personalis, Inc.* | 1,292,508 | 13,403,308 | ||||||
Total Life Sciences Tools & Services | 205,217,889 | |||||||
Technology Hardware, Storage & Peripherals - 1.6% | ||||||||
Pure Storage, Inc., Class A* | 894,170 | 12,876,048 | ||||||
Total Common Stocks (Cost $646,086,950) | 779,833,239 | |||||||
MONEY MARKET FUND–0.4% | ||||||||
Morgan Stanley Institutional Liquidity Fund - Government Portfolio, 0.15%(b) (Cost $3,199,614) | 3,199,614 | 3,199,614 | ||||||
Total Investments–100.3% (Cost $649,286,564) | 783,032,853 | |||||||
Liabilities in Excess of Other Assets–(0.3)% | (2,432,832) | |||||||
Net Assets–100.0% | $ | 780,600,021 |
Schedule of Investments
ARK Genomic Revolution ETF
April 30, 2020 (Unaudited)
Affiliated Issuer Transactions
A summary of the Fund’s transactions with affiliated issuers during the period ended April 30, 2020 is as follows:
Value ($) at 7/31/2019 | Purchases Cost ($) | Sales Proceeds ($) | Net Realized Gain/(Loss) ($) | Net Change in Unrealized Appreciation (Depreciation) ($) | Dividend Income ($) | Capital Gain Distributions ($) | Number of Shares at 4/30/2020 | Value ($) at 4/30/2020 | ||||||||||||||||||||||||
Common Stocks — 21.7% | ||||||||||||||||||||||||||||||||
Biotechnology—13.8% | ||||||||||||||||||||||||||||||||
Arcturus Therapeutics Holdings, Inc. † | ||||||||||||||||||||||||||||||||
13,607,577 | 20,519,497 | (4,290,894 | ) | 1,291,690 | 38,860,728 | – | – | 2,028,655 | 69,988,598 | |||||||||||||||||||||||
Intellia Therapeutics, Inc. † | ||||||||||||||||||||||||||||||||
34,596,666 | 15,332,349 | (5,951,008 | ) | (3,483,073 | ) | (5,860,789 | ) | – | – | 2,571,206 | 34,634,145 | |||||||||||||||||||||
Organovo Holdings, Inc. † | ||||||||||||||||||||||||||||||||
2,223,167 | 1,027,344 | (151,195 | ) | (28,463 | ) | 165,768 | – | – | 7,649,779 | 3,236,621 | ||||||||||||||||||||||
Life Sciences Tools & Services—7.9% | ||||||||||||||||||||||||||||||||
Compugen Ltd. † | ||||||||||||||||||||||||||||||||
9,974,321 | 19,337,536 | (9,162,883 | ) | 1,970,336 | 39,365,194 | – | – | 4,243,237 | 61,484,504 | |||||||||||||||||||||||
60,401,731 | 56,216,726 | (19,555,980 | ) | (249,510 | ) | 72,530,901 | – | – | 16,492,877 | 169,343,868 |
* | Non-income producing security |
† | Affiliated security |
(a) | American Depositary Receipt |
(b) | Rate shown represents annualized 7-day yield as of April 30, 2020. |
Fair Value Measurement
The Fund discloses the fair value of its investments in a hierarchy that distinguishes between: (i) market participant assumptions developed based on market data obtained from sources independent of the Fund (observable inputs) and (ii) the Fund’s own assumptions about market participant assumptions developed based on the best information available under the circumstances (unobservable inputs). The three levels defined by the hierarchy are as follows:
•Level 1— Quoted prices in active markets for identical assets.
•Level 2— Other significant observable inputs (including quoted prices for similar securities, interest rates, prepayment speeds, credit risk, etc.).
•Level 3— Significant unobservable inputs (including each Fund’s own assumptions in determining the fair value of investments).
The inputs or methodology used for valuing securities are not necessarily an indication of the risk associated with investing in those securities.
The following is a summary of the valuations as of April 30, 2020, based upon the three levels defined above:
ARK Genomic Revolution ETF | Level 1 | Level 2 | Level 3 | Total | ||||||||||||
Assets | ||||||||||||||||
Common Stocks(c) | $ | 779,833,239 | $ | – | $ | – | $ | 779,833,239 | ||||||||
Money Market Fund | 3,199,614 | – | – | 3,199,614 | ||||||||||||
Total | $ | 783,032,853 | $ | – | $ | – | $ | 783,032,853 |
(c) Please refer to the Schedule of Investments to view securities segregated by industry type.